Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial
Journal
The Lancet Neurology
Journal Volume
19
Journal Issue
12
Pages
980
Date Issued
2020-12
Author(s)
Meretoja A.
Yassi N.
Wu T.Y.
Churilov L.
Sibolt G.
Kleinig T.
Spratt N.J.
Thijs V.
Wijeratne T.
Cho D.-Y.
Shah D.
Cloud G.C.
Phan T.
Bladin C.
Moey A.
Aviv R.I.
Barras C.D.
Sharma G.
Hsu C.Y.
Ma H.
Campbell B.C.V.
Mitchell P.
Yan B.
Parsons M.W.
Tiainen M.
Curtze S.
Strbian D.
Harvey J.
Levi C.
Donnan G.A.
Davis S.M.
Abstract
Background: Despite intracerebral haemorrhage causing 5% of deaths worldwide, few evidence-based therapeutic strategies other than stroke unit care exist. Tranexamic acid decreases haemorrhage in conditions such as acute trauma and menorrhoea. We aimed to assess whether tranexamic acid reduces intracerebral haemorrhage growth in patients with acute intracerebral haemorrhage. Methods: We did a prospective, double-blind, randomised, placebo-controlled, investigator-led, phase 2 trial at 13 stroke centres in Australia, Finland, and Taiwan. Patients were eligible if they were aged 18 years or older, had an acute intracerebral haemorrhage fulfilling clinical criteria (eg, Glasgow Coma Scale score of >7, intracerebral haemorrhage volume <70 mL, no identified or suspected secondary cause of intracerebral haemorrhage, no thrombotic events within the previous 12 months, no planned surgery in the next 24 h, and no use of anticoagulation), had contrast extravasation on CT angiography (the so-called spot sign), and were treatable within 4·5 h of symptom onset and within 1 h of CT angiography. Patients were randomly assigned (1:1) to receive either 1 g of intravenous tranexamic acid over 10 min followed by 1 g over 8 h or matching placebo, started within 4·5 h of symptom onset. Randomisation was done using a centralised web-based procedure with randomly permuted blocks of varying size. All patients, investigators, and staff involved in patient management were masked to treatment. The primary outcome was intracerebral haemorrhage growth (>33% relative or >6 mL absolute) at 24 h. The primary and safety analyses were done in the intention-to-treat population. The trial is registered at ClinicalTrials.gov (NCT01702636). Findings: Between March 1, 2013, and Aug 13, 2019, we enrolled and randomly assigned 100 participants to the tranexamic acid group (n=50) or the placebo group (n=50). Median age was 71 years (IQR 57–79) and median intracerebral haemorrhage volume was 14·6 mL (7·9–32·7) at baseline. The primary outcome was not different between the two groups: 26 (52%) patients in the placebo group and 22 (44%) in the tranexamic acid group had intracerebral haemorrhage growth (odds ratio [OR] 0·72 [95% CI 0·32–1·59], p=0·41). There was no evidence of a difference in the proportions of patients who died or had thromboembolic complications between the groups: eight (16%) in the placebo group vs 13 (26%) in the tranexamic acid group died and two (4%) vs one (2%) had thromboembolic complications. None of the deaths was considered related to study medication. Interpretation: Our study does not provide evidence that tranexamic acid prevents intracerebral haemorrhage growth, although the treatment was safe with no increase in thromboembolic complications. Larger trials of tranexamic acid, with simpler recruitment methods and an earlier treatment window, are justified. Funding: National Health and Medical Research Council, Royal Melbourne Hospital Foundation. ? 2020 Elsevier Ltd
SDGs
Other Subjects
antithrombocytic agent; hydroxymethylglutaryl coenzyme A reductase inhibitor; placebo; tranexamic acid; antifibrinolytic agent; tranexamic acid; adult; aged; Article; brain hemorrhage; brain ischemia; clinical article; clinical outcome; computed tomographic angiography; controlled study; data analysis software; double blind procedure; drug efficacy; drug safety; female; Glasgow coma scale; human; intention to treat analysis; lung embolism; male; multicenter study; National Institutes of Health Stroke Scale; phase 2 clinical trial; priority journal; prospective study; randomized controlled trial; brain hemorrhage; clinical trial; diagnostic imaging; middle aged; very elderly; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cerebral Hemorrhage; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Tranexamic Acid
Type
journal article